{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:30:02Z","timestamp":1793640602580,"version":"4.5.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100014422","name":"Eli Lilly Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014422","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Tanabe Pharma Corporation","id":[{"id":"https:\/\/ror.org\/038ehsm73","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s13300-026-01916-x","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T07:02:26Z","timestamp":1788850946000},"page":"1639-1653","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tirzepatide Benefit for Early Glycemic and Weight Management in People with T2D in Japan: Rationale, Design, and Baseline Characteristics of T-BEAT Study"],"prefix":"10.1007","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5302-9793","authenticated-orcid":false,"given":"Hironori","family":"Waki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7208-945X","authenticated-orcid":false,"given":"Hideaki","family":"Kagitani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4459-2469","authenticated-orcid":false,"given":"Satoshi","family":"Osaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariko","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5334-7687","authenticated-orcid":false,"given":"Daisuke","family":"Yabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"key":"1916_CR1","doi-asserted-by":"crossref","unstructured":"International Diabetes Federation. Japan. Diabetes country report 2000\u20132050. https:\/\/diabetesatlas.org\/data-by-location\/country\/japan\/.","DOI":"10.5089\/9781451820461.002"},{"key":"1916_CR2","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1111\/jdi.13306","volume":"11","author":"E Araki","year":"2019","unstructured":"Araki E, Goto A, Kondo T, et al. Japanese clinical practice guideline for diabetes 2019. J Diabetes Investig. 2019;11:1020\u201376.","journal-title":"J Diabetes Investig"},{"key":"1916_CR3","unstructured":"FY2021 Basic statistics: Japan Diabetes Clinical Data Management Study Group. 2021. http:\/\/jddm.jp\/public-information\/index-2021\/."},{"key":"1916_CR4","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.2169\/internalmedicine.55.6475","volume":"55","author":"A Goto","year":"2016","unstructured":"Goto A, Noda M, Inoue M, Goto M, Charvat H. Increasing number of people with diabetes in Japan: Is this trend real? Intern Med. 2016;55:1827\u201330.","journal-title":"Intern Med"},{"key":"1916_CR5","unstructured":"Approval of Mounjaro, the world\u2019s first sustained release GIP\/GLP-1 receptor agonist for the treatment of type 2 diabetes in Japan 2022. https:\/\/www.mt-pharma.co.jp\/e\/news\/assets\/pdf\/e_MTPC220926.pdf."},{"key":"1916_CR6","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/S2213-8587(22)00188-7","volume":"10","author":"N Inagaki","year":"2022","unstructured":"Inagaki N, Takeuchi M, Oura T, Imaoka T, Seino Y. Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2022;10:623\u201333.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1916_CR7","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/S2213-8587(22)00187-5","volume":"10","author":"T Kadowaki","year":"2022","unstructured":"Kadowaki T, Chin R, Ozeki A, Imaoka T, Ogawa Y. Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial. Lancet Diabetes Endocrinol. 2022;10:634\u201344.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1916_CR8","unstructured":"List of Approved Drugs. April 2004 to March 2025: Pharmaceuticals and Medical Devices Agency. 2025. https:\/\/www.pmda.go.jp\/files\/000274881.pdf."},{"key":"1916_CR9","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1111\/jdi.14291","volume":"15","author":"D Yabe","year":"2024","unstructured":"Yabe D, Hamamoto Y, Kawanami D, et al. PIONEER REAL Japan: primary results from a multicenter, prospective, real-world study of oral semaglutide in adults with type 2 diabetes in Japanese clinical practice. J Diabetes Investig. 2024;15:1566\u201377.","journal-title":"J Diabetes Investig"},{"key":"1916_CR10","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/S2213-8587(20)30074-7","volume":"8","author":"D Yabe","year":"2020","unstructured":"Yabe D, Nakamura J, Kaneto H, et al. Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial. Lancet Diabetes Endocrinol. 2020;8:392\u2013406.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1916_CR11","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMoa2501006","volume":"392","author":"DK McGuire","year":"2025","unstructured":"McGuire DK, Marx N, Mulvagh SL, et al. Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes. N Engl J Med. 2025;392:2001\u201312.","journal-title":"N Engl J Med"},{"key":"1916_CR12","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s13300-022-01226-y","volume":"13","author":"M Janic","year":"2022","unstructured":"Janic M, Rizzo M, Cosentino F, et al. Effect of oral semaglutide on cardiovascular parameters and their mechanisms in patients with type 2 diabetes: rationale and design of the Semaglutide Anti-Atherosclerotic Mechanisms of Action Study (SAMAS). Diabetes Ther. 2022;13:795\u2013810.","journal-title":"Diabetes Ther"},{"key":"1916_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27134315","author":"VP Chavda","year":"2022","unstructured":"Chavda VP, Ajabiya J, Teli D, Bojarska J, Apostolopoulos V. Tirzepatide, a new era of dual-targeted treatment for diabetes and obesity: a mini-review. Molecules. 2022. https:\/\/doi.org\/10.3390\/molecules27134315.","journal-title":"Molecules"},{"key":"1916_CR14","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2337\/cd19-0079","volume":"38","author":"S Hughes","year":"2020","unstructured":"Hughes S, Neumiller JJ. Oral semaglutide. Clin Diabetes. 2020;38:109\u201311.","journal-title":"Clin Diabetes"},{"key":"1916_CR15","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1111\/jdi.14202","volume":"15","author":"R Bouchi","year":"2024","unstructured":"Bouchi R, Kondo T, Ohta Y, et al. A consensus statement from the Japan Diabetes Society: a proposed algorithm for pharmacotherapy in people with type 2 diabetes\u20142nd edition (English version). J Diabetes Investig. 2024;15:1326\u201342.","journal-title":"J Diabetes Investig"},{"key":"1916_CR16","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s12325-020-01561-1","volume":"38","author":"A Igarashi","year":"2021","unstructured":"Igarashi A, Bekker Hansen B, Langer J, et al. Preference for oral and injectable GLP-1 RA therapy profiles in Japanese patients with type 2 diabetes: a discrete choice experiment. Adv Ther. 2021;38:721\u201338.","journal-title":"Adv Ther"},{"key":"1916_CR17","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1007\/s13300-025-01794-9","volume":"16","author":"MM Hoog","year":"2025","unstructured":"Hoog MM, Vallarino C, Maldonado JM, et al. Real-world effectiveness of tirzepatide versus semaglutide on HbA1c and weight in patients with type 2 diabetes. Diabetes Ther. 2025;16:2237\u201356.","journal-title":"Diabetes Ther"},{"key":"1916_CR18","doi-asserted-by":"publisher","first-page":"5661","DOI":"10.1111\/dom.15934","volume":"26","author":"MS Kelly","year":"2024","unstructured":"Kelly MS, Scopelliti EM, Goodson KE, Lo CMA, Nguyen HX, Simon B. Real-world evaluation of the effects of tirzepatide in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2024;26:5661\u20138.","journal-title":"Diabetes Obes Metab"},{"key":"1916_CR19","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s13300-024-01684-6","volume":"16","author":"R Mody","year":"2025","unstructured":"Mody R, Desai K, Teng CC, et al. Characteristics and dosing patterns of tirzepatide users with type 2 diabetes in the United States. Diabetes Ther. 2025;16:307\u201327.","journal-title":"Diabetes Ther"},{"key":"1916_CR20","doi-asserted-by":"publisher","first-page":"3381","DOI":"10.1111\/dom.15680","volume":"26","author":"A Buckley","year":"2024","unstructured":"Buckley A, Suliman S, Allum M, et al. Real world use of tirzepatide in the treatment of type 2 diabetes in an Arab population. Diabetes Obes Metab. 2024;26:3381\u201391.","journal-title":"Diabetes Obes Metab"},{"key":"1916_CR21","doi-asserted-by":"publisher","first-page":"12-PUB","DOI":"10.2337\/db24-12-PUB","volume":"73","author":"S Kaneko","year":"2024","unstructured":"Kaneko S, Asai Y, Nakazaki A, Ito S, Hirobata T. 12-PUB: tirzepatide\u2014Efficacy, safety, and satisfaction in real world type 2 diabetes application in Japan. Diabetes. 2024;73:12-PUB.","journal-title":"Diabetes"},{"key":"1916_CR22","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1111\/jdi.14219","volume":"15","author":"R Suzuki","year":"2024","unstructured":"Suzuki R, Amadid H, Major-Pedersen A, Yabe D. PIONEER REAL Japan: baseline characteristics of a multicenter, prospective, real-world study of oral semaglutide in adults with type 2 diabetes in clinical practice in Japan. J Diabetes Investig. 2024;15:1047\u201356.","journal-title":"J Diabetes Investig"},{"key":"1916_CR23","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1016\/j.jdiacomp.2017.03.011","volume":"31","author":"L Ji","year":"2017","unstructured":"Ji L, Bonnet F, Charbonnel B, et al. Towards an improved global understanding of treatment and outcomes in people with type 2 diabetes: rationale and methods of the DISCOVER observational study program. J Diabetes Complicat. 2017;31:1188\u201396.","journal-title":"J Diabetes Complicat"},{"key":"1916_CR24","first-page":"809","volume":"192","author":"H Ishii","year":"2000","unstructured":"Ishii H, Bradley C, Riazi A, Barendse S, Yamamoto T. The Japanese version of the Diabetes Treatment Satisfaction Questionnaire (DTSQ): translation and clinical evaluation. J Clin Exp Med. 2000;192:809\u201314.","journal-title":"J Clin Exp Med"},{"key":"1916_CR25","unstructured":"Bradley C. The Diabetes Treatment Satisfaction Questionnaire: DTSQ. In: Bradley C, editor. Handbook of Psychology and Diabetes: a guide to psychological measurement in diabetes research and practice: formerly published by Harwood Academic Publishers; 1994. p. 111\u201332."},{"key":"1916_CR26","doi-asserted-by":"publisher","first-page":"530","DOI":"10.2337\/diacare.22.3.530","volume":"22","author":"C Bradley","year":"1999","unstructured":"Bradley C. Diabetes treatment satisfaction questionnaire. Change version for use alongside status version provides appropriate solution where ceiling effects occur. Diabetes Care. 1999;22:530\u20132.","journal-title":"Diabetes Care"},{"key":"1916_CR27","first-page":"809","volume":"8","author":"T Fukaishi","year":"2025","unstructured":"Fukaishi T, Ishibashi F. Improvement of quality of life by switching from Oral Semaglutide to Tirzepatide in patients with type 2 diabetes. JMA J. 2025;8:809\u201316.","journal-title":"JMA J"},{"key":"1916_CR28","unstructured":"Novo Nordisk Rybelsus (semaglutide) tablets [prescribing information] Plainsboro: Novo Nordisk; 2024. https:\/\/www.novo-pi.com\/rybelsus.pdf."},{"key":"1916_CR29","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1007\/s13300-025-01739-2","volume":"16","author":"R Suzuki","year":"2025","unstructured":"Suzuki R, Chand K, Taguchi Y. Perceptions and attitudes toward oral semaglutide among Japanese physicians and individuals with type 2 diabetes: a web-based survey. Diabetes Ther. 2025;16:1479\u201395.","journal-title":"Diabetes Ther"},{"key":"1916_CR30","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S0140-6736(24)00537-3","volume":"404","author":"AI Adler","year":"2024","unstructured":"Adler AI, Coleman RL, Leal J, Whiteley WN, Clarke P, Holman RR. Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91). Lancet. 2024;404:145\u201355.","journal-title":"Lancet"},{"key":"1916_CR31","doi-asserted-by":"publisher","first-page":"75","DOI":"10.2337\/db24-0166","volume":"74","author":"GT Russo","year":"2025","unstructured":"Russo GT, Nicolucci A, Lucisano G, et al. When does metabolic memory start? Insights from the Association of Medical Diabetologists Annals Initiative on stringent HbA1c targets. Diabetes. 2025;74:75\u201381.","journal-title":"Diabetes"},{"key":"1916_CR32","doi-asserted-by":"publisher","first-page":"305","DOI":"10.3803\/EnM.2023.1690","volume":"38","author":"CRL Cardoso","year":"2023","unstructured":"Cardoso CRL, Leite NC, Salles GF. Effects of weight loss and interaction with physical activity on risks of cardiovascular outcomes in individuals with type 2 diabetes. Endocrinol Metab. 2023;38:305\u201314.","journal-title":"Endocrinol Metab"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-026-01916-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-026-01916-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-026-01916-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:03:26Z","timestamp":1793639006000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-026-01916-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":32,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1916"],"URL":"https:\/\/doi.org\/10.1007\/s13300-026-01916-x","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]},"assertion":[{"value":"2 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Hironori Waki has received consulting fees from AstraZeneca K.K., Eli Lilly Japan K.K., and Novo Nordisk Pharma Ltd. He also received payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing, or educational events from Abbott Japan LLC, Astellas Pharma Inc., AstraZeneca K.K., Bayer Yakuhin Ltd., Daiichi Sankyo Co., Ltd., Dexcom Japan LLC, Eisai Co., Ltd., Eli Lilly Japan K.K., FUJIFILM Toyama Chemical Co., Ltd, Hisamitsu Pharmaceutical Co., Inc, Kowa Company, Ltd., Kyowa Kirin Co., Ltd., LifeScan Japan K.K., Tanabe Pharma Corporation, MSD K.K., Nippon Boehringer Ingelheim Co., Ltd., Novartis Pharma K.K., Novo Nordisk Pharma Ltd., Ono Pharmaceutical Co., Ltd, Sanofi K.K., Sumitomo Pharma Co., Ltd., Taisho Pharmaceutical Co., Ltd., Taisho Toyama Pharmaceutical Co., Ltd., Teijin Pharma Limited, and Tsumura & Co. Hideaki Kagitani, Satoshi Osaga, and Mariko Inoue are employees of Eli Lilly Japan K.K. Satoshi Osaga may own stock\/stock options of Eli Lilly and Company. Daisuke Yabe received clinically commissioned\/joint research grants from Nippon Boehringer Ingelheim Co., Ltd., Taisho Pharmaceutical Co., Ltd., Arkray, Inc., and Novo Nordisk Pharma Ltd. and consulting fees from Kansai Medical Net Co. Ltd., Eli Lilly Japan K.K., Sanofi K.K., Nippon Boehringer Ingelheim Co., Ltd., and Novo Nordisk Pharma Ltd. He also received payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing, or educational events from Tanabe Pharma Corporation, Eli Lilly Japan K.K., Novo Nordisk Pharma Ltd., Sanofi K.K., Kowa Co. Ltd., Sumitomo Pharma Co. Ltd., Taisho Pharmaceutical Co., Ltd., Ono Pharmaceutical Co. Ltd., and Nippon Boehringer Ingelheim Co., Ltd. He serves in a paid\/unpaid leadership or fiduciary role in the International Diabetes Federation Western Pacific Region, Executive Board; The European Association for the Study of Diabetes, Global Council; The Japan Society of Clinical Nutrition and Metabolism, Executive Board; The Japan Society of Diabetes Complication, Executive Board; The Japan Society of Informatics for Diabetes Mellitus, Vice President; The Asina Association for the Study of Diabetes, Executive Board; The Japan Diabetes Society, Auditor; The Japan Endocrine Society, Executive Board; The Japan Society of Constitutional Medicine, Executive Board; and The Japan Association for Diabetes Care and Education, Executive Board.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study involving multiple research institutes was approved by Takahashi Clinic Ethics Committee as a centralized application (approval number: LNW00221 dated 21 May 2024). The study was conducted per ethical principles outlined in the Declaration of Helsinki and was compliant with the Japanese \u201cEthical Guidelines for Medical and Biological Research Involving Human Subjects.\u201d","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}